Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 8/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 8/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.51 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4166142 | 0.89 | S1PR4 (0.45) | S1PR4S1PR1S1PR5SCN10ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4146413 | 0.88 | S1PR4 (0.44) | S1PR4S1PR1S1PR5SCN10ASMN1; SMN2 | |
| SCHEMBL5110667 | 0.88 | SCN10A (0.56) | S1PR4S1PR1S1PR5SCN10APPARA | |
| Trifluoroacetic Acid SCHEMBL4157721 | 0.87 | S1PR4 (0.46) | S1PR4S1PR1S1PR5SCN10APPARA | |
| Trifluoroacetic Acid SCHEMBL4164102 | 0.86 | S1PR4 (0.47) | S1PR4S1PR1S1PR5SCN10ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4154336 | 0.86 | S1PR4 (0.47) | S1PR4S1PR1S1PR5SCN10ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4144867 | 0.85 | S1PR4 (0.44) | S1PR4S1PR1S1PR5SCN10APPARA | |
| Trifluoroacetic Acid SCHEMBL4153478 | 0.83 | S1PR4 (0.43) | S1PR4S1PR1S1PR5SCN10AOPRM1 | |
| Trifluoroacetic Acid SCHEMBL4150060 | 0.80 | S1PR4 (0.38) | S1PR4S1PR1S1PR5SCN10AKDM4E | |
| Trifluoroacetic Acid SCHEMBL4150163 | 0.80 | S1PR4 (0.40) | S1PR4S1PR1S1PR5KDM4EOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-7429597-B2 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-09-30 | — | — | US | disclosed |
| EP-1583757-A1 | NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-10-12 | — | — | EP | disclosed |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004058743-A1 | NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | F11, F12, F2 | S1PR4 4711/4885S1PR1 3898/4885S1PR5 4042/4885 |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | S1PR4 4618/4885S1PR1 4147/4885S1PR5 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.